Black Friday saleUp to 70% OFF
CCC

CYCLOPHARM LIMITED

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Forecast Seasonals

CYC chart


Full chart

CYC upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪150.03 M‬ AUD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.100 AUD
Net income (FY)
‪−4.70 M‬ AUD
Revenue (FY)
‪27.14 M‬ AUD
Shares float
‪59.35 M‬
Beta (1Y)
−0.29

Employees


Employees (FY)
87
Change (1Y)
+24 +38.10%
Revenue / Employee (1Y)
‪212.37 K‬ AUD
Net income / Employee (1Y)
‪−36.78 K‬ AUD

About CYCLOPHARM LIMITED


Sector
Health Technology
Industry
Medical Specialties
CEO
James M. McBrayer
Website
cyclopharm.com
Headquarters
Kingsgrove
Founded
2005
ISIN
AU000000CYC5
FIGI
BBG000QFS060
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in diagnostic imaging in lung health. It manufactures and sells medical devices and pharmaceutical products. It operates through Technegas and Molecular Imaging segments. The Technegas segment supplies diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The company was founded in 1984 and is headquartered in Kingsgrove, Australia.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CYC news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CYC is 1.570 AUD — it has increased by 8.15% in the past 24 hours. Watch CYCLOPHARM LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange CYCLOPHARM LIMITED stocks are traded under the ticker CYC.
CYC stock has risen by 5.80% compared to the previous week, the month change is a −5.19% fall, over the last year CYCLOPHARM LIMITED has showed a −23.41% decrease.
We've gathered analysts' opinions on CYCLOPHARM LIMITED future price: according to them, CYC price has a max estimate of 2.70 AUD and a min estimate of 2.70 AUD. Watch CYC chart and read a more detailed CYCLOPHARM LIMITED stock forecast: see what analysts think of CYCLOPHARM LIMITED and suggest that you do with its stocks.
CYC reached its all-time high on Jan 27, 2021 with the price of 3.450 AUD, and its all-time low was 0.100 AUD and was reached on Mar 22, 2013. View more price dynamics on CYC chart.
See other stocks reaching their highest and lowest prices.
CYC stock is 11.73% volatile and has beta coefficient of −0.29. Track CYCLOPHARM LIMITED stock price on the chart and check out the list of the most volatile stocks — is CYCLOPHARM LIMITED there?
Today CYCLOPHARM LIMITED has the market capitalization of ‪150.03 M‬, it has increased by 1.11% over the last week.
Yes, you can track CYCLOPHARM LIMITED financials in yearly and quarterly reports right on TradingView.
CYCLOPHARM LIMITED is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
CYCLOPHARM LIMITED revenue for the last half-year amounts to ‪13.32 M‬ AUD, despite the estimated figure of ‪15.20 M‬ AUD. In the next half-year revenue is expected to reach ‪14.90 M‬ AUD.
CYC net income for the last half-year is ‪−7.51 M‬ AUD, while the previous report showed ‪−1.81 M‬ AUD of net income which accounts for −315.94% change. Track more CYCLOPHARM LIMITED financial stats to get the full picture.
As of Nov 28, 2024, the company has 87.00 employees. See our rating of the largest employees — is CYCLOPHARM LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CYCLOPHARM LIMITED EBITDA is ‪−13.88 M‬ AUD, and current EBITDA margin is −29.27%. See more stats in CYCLOPHARM LIMITED financial statements.
Like other stocks, CYC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CYCLOPHARM LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CYCLOPHARM LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CYCLOPHARM LIMITED stock shows the sell signal. See more of CYCLOPHARM LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.